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Historically it has been the privilege of each country to define rules and regulations of 
its patent system, scope of patenting, exceptions and enforcement mechanism. This 
had resulted in sharp differences in patenting provisi ns in different countries; 
particularly the differences were substantial betwen developed and developing 
countries. Majority of the developing countries like India had limited term of 
patenting, product patents were not allowed in some s ctors (mainly 
‘pharmaceutical’), etc and enforcement mechanism was not so strong. This type of 
patent system was in force in developing primarily to enable industries in these 
countries to catch up with their counterparts in the industrialised economies. The 
multilateral trade agreement, the WTO (World Trade Organisation) enacted in 1994, 
enforced new rules and regulations for trade between countries. It was for the first 
time through the TRIPS (Trade Related Intellectual Property Rights) agreement in the 
WTO, protection and safeguard of intellectual propety rights was introduced in trade 
between countries.  
 
International trade is increasingly becoming technology driven. Share of high 
technology goods in export is becoming important comp nent of international trade 
particularly by developed countries. In this technology driven market, creation and 
successful translation of proprietary knowledge allow firms to be competitive.  Firms 
have increasingly complained that there are widespread infringements of their 
protected technologies particularly in developing countries due to weak patent laws 
and inadequate enforcement mechanism. This has beenthe major argument for 
inclusion of IPR provisions in international trade agreement i.e. the Agreement 
establishing the World Trade Organisation (the WTO Agreement) (However, this 
argument has also come in for criticism as it has been argued by developing countries 
as well as international agencies such as the WHO, that inclusion of stringent IPR 
provisions can retard the growth of countries which are in different stages of 
development).  
 
TRIPS agreement has three broad components: (A) Goals, objectives and standards of 
IPR, (B) Mechanism for enforcement, (C) Specific needs of developing countries. 
This agreement, explicitly defined through various articles, specifies the patent 
provisions that member countries would have to provide in their patent law. Thus in 
other words it essentially leads to the creation of a harmonised patent system i.e. to a 
large extent creating similar patent rules and regulations in member countries.  
 
The present article by taking the case of India, a country in transition and a member of 
the WTO, examines the changes that were undertaken by it in its patent provisions to 
comply with the TRIPS agreement. The article also underscores the plausible 
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implications of these changes. In a broad sense the si uation in India i.e. the patent 
system in the country and the effect of TRIPS agreement would be similar to other 
developing economies. The paper is articulated in five main sections.  Section 2 looks 
at Indian Patent System) for patenting in India and the major deviations from the 
TRIPS agreement. Section 3 covers changes that were required in the Indian Patent 
Act to comply with the TRIPS agreement. Section 4 discusses the plausible 
implications of the amendments. Section 5 examines India’s preparedness by 
examining patenting trends of Indian firms. This section also covers impact of India 
joining Patent Cooperation Treaty (PCT) by observing patent filing by Indian firms 
through the PCT route as well as foreign patents that are entering India through this 
route. Section 6 highlights the main findings that emerge from this study and their 
implications.   
 
Indian Patent System 
The patent system was first introduced in India in 1856 through the Exclusive 
Privileges Act, 1856. This act provided exclusive right to the patent holder for a 
period of 14 years. The Indian Patents & Design Act, 1911, replaced the previous act, 
although the main clauses remained the same. The patent right was provided for 16 
year. The Indian Patent Act of 1970 that came into force from 1971 made significant 
changes. This act limited the scope of patent by defining inventions that can be 
patented and introduced a number of exclusions. A major exclusion was discontinuing 
product patents in pharmaceuticals, food and agrochemicals. Patenting of process was 
restricted to seven years (or five years from the date of sealing the patent, whichever 
was shorter).  
 
The 1970 Act also defined the provisions that residnts had to follow for patenting 
outside India (apart from the patent rules in the country of patenting). It can be 
concluded that the Indian Patent Act of 1970 was enunciated to help Indian industry 
in technology substitution (creating alternate products of patented technologies) by 
restricting the scope and terms of patenting. This act was instrumental in creating 
opportunities for Indian pharmaceutical firms to create generic drugs. There were 
other provisions in this Act that helped Indian industry in general to overcome 
barriers of patented technology. 
 
TRIPS and the Indian Patent System  
The WTO is essentially a rule based multilateral trding system and the member 
countries have to necessarily comply with all the Agreements. The WTO agreement is 
an umbrella agreement2. Annexed to it are various agreements covering trade in 
services, goods, intellectual property, dispute settlement, etc.  Agreement on 
intellectual property is governed by the TRIPS agreem nt. TRIPS agreement has far 
reaching implications as it brings in protection of intellectual property rights in trade 
between countries. TRIPS agreement contains general provisions and basic principles 
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1st January, 1995. Upon signing the new WTO agreements (which include the updated GATT, known 
as GATT 1994), signatories officially became known as “WTO members”.  
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that are to be followed for IPR protection of all types (Watal, 2000). The subsequent 
sections cover specific guidelines for each type of IPR, rules for enforcement, 
acquisition and maintenance, dispute prevention and settlement, and transitional 
agreement.   
 
Form 1971 onwards, Indian Patent Act of 1970 governed the patent system in the 
country. This act was not in compliance with TRIPS provisions. India being a 
member of the WTO it was obligatory for India to change its patent act to confirm 
with the TRIPS Agreement. In principle there were three major changes that were 
required in the above act. The first deadline was to be adhered on the day the WTO 
agreement came into force (1st January, 1995): (a) to introduce ‘Mailbox’ protection 
(providing a means by which product patents in pharmaceutical and agriculture can be 
filed) and (b) provision of exclusive marketing rights (EMRs) to a pharmaceutical 
product that has been granted patent in any WTO member country after 1995. These 
changes had to be made in patent laws of country such as India that did not provide 
product patents in pharmaceuticals and agro-chemicals. The second major change 
required was to increase the duration for patent protection to 20 years from the date of 
filing of a patent by 2000. The third major requirement was to introduce product 
patents in pharmaceuticals, food and agro-chemicals by 2005. In principle by 2005, 
Indian Patent Act had to be made complaint with TRIPS requirements. 
 
Apart from meeting the three deadlines, other important changes were required to be 
incorporated in Indian patent Act by 2005. TRIPS include a number of provisions 
from other major treaties covering IPR. In framing its rules/guidelines in patents, it 
has included articles from Paris Convention. Additionally India has also signed PCT 
(Patent Cooperation Treaty) and Budapest Treaty and thus it was imperative for India 
to include all the major clauses in its Patent Act that were required by these treaties.  
 
Amendments in the Indian Patent Act 
Amendments in the Indian Patent Act of 1970 were thus required keeping in view the 
deadlines imposed. In other words by 2005 Indian Patent Act had to meet the entire 
obligatory clauses covered by TRIPS. India’s accession to PCT and Budapest Treaty 
also required additional changes or provisions in patent filing (PCT) and providing 
designated centres for deposition of micro-organism (Budapest Treaty). 
 
The Indian Government drafted the Patent Amendment Bill in 1995 but this bill could 
not be passed by Parliament. Only in 1999, the first amendment was made in the 
Patent Act of 1970. This amendment was consequent to a WTO ruling following a 
complaint filed by the European Union and the US against India at the WTO citing 
India’s failure to comply with Article 70.8 i.e. ‘Mailbox’ provision) and Article 70.9 
(provision of Exclusive Marketing Rights i.e. EMRs). The WTO ruled that India was 
in default of its obligations and also India was obligated to have a transitional system 
in place immediately. Keeping this ruling in view, amendment was made in 1999, to 
allow EMRs and Mailbox facility.  It was also notified that this act would come into 
force from 1995.   
 
The Patents (Amendment) Act, 1999 specified four pre-conditions to be met by an 
EMR applicant: (a) The applicant must hold a valid patent on pharmaceutical product 
granted after January 1, 1995 in any of the WTO member countries (countries who 
are also WTO members); (b) The applicant should have marketing rights in the 
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member countries; (c) A product patent application should already have been made in 
India, and (d) Marketing approval of the same product should have been granted in 
India. The first three conditions were as per the stipulation of TRIPS agreement. The 
fourth clause was incorporated to meet the Indian drug regulatory approval. The 
EMRs were to be given for a period of 5 years as per TRIPS requirement. The other 
important change made was the removal of restriction on residents to apply for 
patents outside India. In the Patent Act (1970) it was obligatory for residents (section 
39) to seek prior permission before applying for patents outside India. 
 
Patents Amendment Act 2002 incorporated the 20 years pe iod of protection for 
granted patents from the date of filing of patents i  India. Some other important 
changes made were: (a) Redefining the scope of invention. Of particular significance 
were (i) allowing patents for treatment of plants (medicinal, surgical, curative and 
prophylactic process) to render them free of diseases or to increase their economic 
value or that of their products, and (ii) allowing patents covering micro-organisms;  
(b) The source of geographical origin of biological material used in invention was 
made mandatory to be disclosed in the invention. A list of Authorized Depository 
Institutions were notified in the gazette of India, Part II, Section 3 for depositing the 
biological materials mentioned in the specification at the time of filing a patent 
application. This change was made as per compliance with Budapest Treaty;  (c) 
Request for examination introduced implying all patent application in which First 
Examination Report have not been issued on or before 19th May 2003 were to be 
examined in serial order in which the request for examination is filed. ;(d) Reversal of 
burden of proof in case of process patent infringement from patent holder to the 
infringer (this was a requirement under TRIPS). The defendant has to prove that 
process used by him/her to obtain a product (identical o the product obtained by a 
patented process) is different from the patented process. The patentee is only required 
to prove that the product is identical to the product obtained by the patented process. 
(e) Provisions were made for filing as well as receiving patent application through 
PCT. 
 
Additionally new grounds of opposition were introduced covering: (a) Non-disclosure 
or wrongly mentioning the source of geographical origin of biological material used 
in invention.;(b) Anticipation having regard to the knowledge oral or otherwise 
available within the local indigenous community in India or elsewhere. As per TRIPS 
agreement, patent or some form of protection had to provided for protecting plant 
varieties. Government introduced “protection of plant varieties and farmer’s rights 
act” (PPVFR 2001) for providing protection to various plant related/derived products 
(plant extracts, various compositions derived from plant products). 
 
The present Act, The Patents (Amendment) Act 2005 has incorporated a major 
change in the Patent Act of 1970 by allowing product patents in all fields of 
technology. Thus it has removed the restriction on product patents in pharmaceuticals, 
food and agro-chemicals. Another important provision has been made regarding 
provision of compulsory license to countries which have insufficient or no 
manufacturing capacity to meet public health situatons.   
 
Like most countries, priority is established strictly by filing date in India. This 
confirms to TRIPS agreement. TRIPS require WTO member countries to comply with 
most of the important articles of Paris Convention. This includes the clause of 
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National Treatment and Right of Priority (Ganguli, 2001).  National treatment implies 
member states must grant the same protection to nati nals of the other members as it 
grants to its own nationals. Right of Priority implies application made within one year 
from the first application in any member state will have the same priority if they file 
application within 12 months in another member country. Further, applicant will have 
freedom to exploit his invention in any member country without loosing novelty due 
to disclosure. These provisions are now applicable for patenting in India. 
 
Table 1 illustrates the major changes that were made in the Indian Patent Act of 1970.  
 
Table 1 
 Major Amendments Incorporated in Indian Patent Act 1970 to comply 
with the TRIPS Agreement 




Only process not 
product patents in food, 
medicines, chemicals 
 
Process and product 
patents in almost all fields of 
technology 
To be fully 
implemented as per 
TRIPS in 2005. 
(Patent Amendment 
Act 2005) 
Term of patents 14 
years; 5-7 years chemicals, 
drugs 
 
Term of patent 20 
years 
Now confirms 
to TRIPS requirement 
(Patent Act 1999)  
Several areas 
excluded from patents 
(method of agriculture, any 
process for medicinal, 
surgical or other treatment 
of humans, or similar 
treatment of animals or 
plants to render them free of 
disease or increase 
economic value of products) 
 
Almost all fields of 
technology patentable. Plant 
varieties excluded from 
patent protection, but 
confusion exists on 




exception allowed by 
TRIP’s. Rules out the 
patenting of living 
things or non-leaving 
substances occurring 
in nature, and further 
rejects the patenting of 
animal and plants. 
         Patent holder to prove 
that the patented process has 
been infringed in creating a 
product. 
Reversal of burden of 
proof in case of process 
patent infringement from 
patent holder to the infringer 
Now confirms to 
TRIPS requirement 
 
    Government allowed to 
use patented invention to 
prevent scarcity 
     Very limited scope for 
governments to use patented 
inventions 
  Now confirms to 
TRIPS requirement 
 
Source: Indian Patent Act 1970 and Rules 1991, GATT Agreemnts: results of 
the Uruguay Round, World Trade Centre, January 1995, Patent Act 1999, Patent Bill, 
2002, Patent Rules 2003, Patent Ordinance 2004 and The Patents Amendment Act, 
2005. 
 
Plausible Implications of the Amendments 
The stronger patent protection provided by the Patent (Amendment) Act 2005 would 
have impact across all the technological sectors. In complex technology areas that 
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have multiple applications (such as information and communication technology, 
biotechnology), patented technologies would increasingly dominate the market. A 
substantial amount would have to be spent by Indian firms towards royalties and 
license fees. Foreign Direct Investment (FDI) in these sectors would include a major 
share in technology transfer comprising of patented technology. Thus increasingly 
Indian market would become technology driven market. 
 
 However, the main impact would be in the pharmaceuti als industry as product 
patent in pharmaceutical sector is possible by the Pat nt (Amendment) Act 2005. Post 
1995 generic versions of patented drugs would have to withdrawn from the market. 
The criteria of patentability, compulsory license and other provisions would mainly 
effect patenting in this sector.  
 
Presently, Indian firms dominate the market accounting for 75% of the drugs that are 
sold. The domestic firms meet 90% of the country’s pharmaceutical demand including 
almost all of the 300 essential drugs. The present ituation was largely due to the 
Patent Act of 1970. Prior to 1970, Indian drug industry accounted for only about 25 % 
of the bulk drugs. The absence of product patent protection for pharmaceuticals and 
agrochemicals led many multinationals to limit their portfolios to patent expired 
products or a few selected patented products. This resulted in an erosion of their 
market share because local manufacturers introduced advanced medicines through 
reverse engineering (simple change in the process). However, sometimes to develop a 
new process (non-infringing) in itself requires considerable skill. Drugs, particularly 
those that are block-buster have a large number of patented process to prevent the 
entry of generics. For example, Eli Lilly protected the production of cefaclor through 
thirty-two processes.  Inspite of the large number of patented process, Ranbaxy could 
develop a new and superior non-infringing process (Chudhuri, 2005).  
 
Foreign firms were required to pay royalties for inter ational drugs, while Indian 
companies could access the newest molecules from all over the world and reformulate 
them for sale in the domestic market. This thus result d in the systematic weakening 
of patent rights for pharmaceutical products in India and helped domestic firms to 
overcome the patent barriers. This situation also put India in an enviable position 
among developing countries in generic drug formulation. 
 
The direct implications of TRIPS would be that products that have been on the market 
before the signing of products patent will remain free of product patent; companies 
that produce any of these products will be able to continue as before. On the other 
hand products patented post-1995 will be protected th reafter (Bhattacharya, 2004). 
Companies that produce products that fall under patent protection will have to stop 
manufacturing them or negotiate a licensing agreement with the (foreign) patent 
holder. The transition will cause move towards a monopoly market. Chemically 
identical products that were there in the market would cease to be available. Non-
identical products that perform the same function i.e. substitutes would remain. These 
substitutes can be patent protected or can be off patent generic drugs. Thus the future 
market would be of three kinds (a) patent drug (b) generic versions of drugs that are 
off patent, and (c) non-bio equivalent drugs.    
 
Another major impact would be in filing patents. Accession to PCT in 1998 has 
opened another route for Indian institutions/indiviuals for filing patents in different 
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countries. The PCT provisions helps in filing patent as an international patent through 
the Indian Patent Office. The countries that the applicant wishes to protect his/her 
invention is marked as designated country(ies) in the patent document. PCT route 
allows cost saving, not going through the trouble of filing the patent in each country 
as well as it maintains priority for at-least 12 months. Similarly, foreign applications 
can file patents in India through the PCT route by designate India in their PCT patent.  
 
Some Indications from Indian patenting Trends 
The main implications of the new patent act would be in the pharmaceutical sector as 
discussed above.  Patents play a primary role in the p armaceutical industry as 
investments are huge as well as risky but where product imitation requires minimal 
investment and capability. It would be imperative for Indian firms to develop 
proprietary products (products that do not infringe upon other patented product) in the 
new patent regime. The products can be chemically non-identical or new-patented 
product. Additionally multiple patented process will have to be developed making the 
product difficult to infringe upon others.  
 
Patenting activity in pharmaceuticals is very high worldwide. For example in the ten-
year period (1990-2000), almost Fifty-Three thousand patents were granted to this 
sector by the USPTO (United States Patent and Tradem rk Office). There has been 
doubling in the patents being granted from 1997 onwards with respect to the number 
of patents in 1990. In comparison Indian patenting activity in pharmaceuticals is 
insignificant. However, as Table 2 and Table 3 indicates, in the overall Indian 
patenting activity pharmaceutical was the dominant rea in which patents were 
granted to Indian entities (NISTADS, 2005). This was true for both the USPTO and 
the IPO.  
  
Table2 
Patenting Activity in Major Sectors during Pre/Post WTO, and Current 
period by Indian entities in USPTO* (1990-2002) 
 








(% of total) 
Pharmaceuticals 9 48 227 284 (42%) 
Chemical 24 42 166 232 (35%) 
Miscellaneous 8 15 42 65 
Biotechnology** 0 7 46 53 
Machinery 7 6 15 28 
Instruments - 5 13 18 
Electronics - 2 7 9 
Transport - - 6 6 
Electrical 
Equipment 
- - 1 1 
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Source: Indian Patenting Activity in International nd Domestic Patent System: 
Contemporary Scenario (NISTADS, 2005)  
 *USPTO (United States Patents and Trademark Office). In this period, 669 
patents were granted to Indian institutions. 
  ** patents in biotechnology were culled out from other s ctors (mainly they 




 Patenting Activity in Major Sectors during Pre/Post WTO, and Current 
period by Indian entities in IPO* (1990-2002) 
 





 (1990-2002)  
(% of total) 
Chemical 419 492 668 1579 (33%) 
Pharmaceuticals 221 305 547 1073 (22%) 
Miscellaneous 234 333 352 919 (19%) 
Machinery 201 267 223 691 (14%) 
Instruments 48 71 81 200 (4%) 
Biotechnology 32 38 60 130 (3%) 
Transport 38 41 43 122 (2%) 
Electrical Equipment 39 30 30 99 (2%) 
Electronics 15 17 42 74 (2%) 
Source: Indian Patenting Activity in International and Domestic Patent  System: 
Contemporary Scenario (NISTADS, 2005)  
*IPO (Indian Patent Office). In this period, 4848 patents of Indian institutions were 
accepted by the patent office. 
 
USPTO allows for product patents in pharmaceuticals, food and agro-chemical. 
Patents granted in pharmaceuticals, food and agro-chemicals by USPTO to Indian 
entities, were distinguished further in terms of protection they had obtained (process, 
product or both). Table 4 exhibits this distinction.  
 
Table 4 
Product/Process Patents in Pharmaceutical, Food & Beverages, and 
Agrochemicals (1990-2002) 
 




Pharmaceuticals 133 73 80 
Pesticides, 
Agrochemical products 
9 4 11 
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3 2 1 
Source: Indian Patenting Activity in International and Domestic Patent  System: 
Contemporary Scenario (NISTADS, 2005)  
 
Above table shows that Indian firms have been able to obtain product patents in the 
three areas (pharmaceuticals, food and agro-chemicals) th t were not allowed by the 
Indian Patent Act of 1970. This provides an indirect indication of the capability of 
Indian firms in undertaking innovation activity tha can lead to product patents filing 
that the new Indian Patent Act (2005) allows. However, this also includes patents 
granted to Incrementally Modified Drugs (IMD). These can be new formulation, new 
combinations of existing NCE (New molecular entity), and new salts and esters of 
existing NCEs. The Indian Patent Amendment Act (2005) does not allow patenting for 
IMD (also sometimes called as secondary patents). 
 
Mailbox’ provision that allowed for product patent filing in pharmaceuticals in the 
Indian Patent Office during the transition period (in principle from 1999 to 31st 
December 2004) show the heightened activity of foreign companies. There are 
already around 5,000 product patent applications in the mailbox, which will now, to 
be taken up for examination. Most of these were fild by MNC’s. This gives an 
indication of the monopolistic market that may emerge after 2005. Foreign firms 
however did not actively purse EMR route during the transition period. The stringent 
conditions for granting EMRs may be responsible for this. The Indian Patent Office 
granted only three EMRs. These EMRs were Nadoxin (Nadifloxacin), anti-infective 
of Wockardt and Cialis (tadalafil, anti-impotency drug of Eli Lilly. An EMR granted 
to Glivec (for treatment of cancer) of Novartis has been challenged and is under 
litigation (ICAR, 2002). 
 
Examination of Indian patenting activity in PCT revealed that Indian organisations 
were beginning to take advantage of PCT route for filing international patents. At the 
same time foreign organisations were also observed to be shifting to this route for 
patent filing in India. India is the leading country among the developing countries in 
terms of patent filing through PCT. One notable feature of the WIPO (World 
Intellectual Property Organisations) data on PCT patent filings by Indian firms is the 
dominant presence of pharmaceutical and biotechnology firms that had taken this 
route for international filing. Except one, all the Indian firms that filed for five or 
more patents under PCT during 1999-02 was either a pharma or a biotech company 




Indian Patenting Activity in the PCT: 1999-2002 




Individuals-4, Dr. Reddy's Research 
Foundation, Nile Limited,Varma Trafag Limited 
2000 54 Dr. Reddy's Research Foundation-7, Dabur 
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Research Foundation-2, Lakshmi Machine Works 
Limited-2, 
2001 122 
CSIR-12,Biocon India Limited-5, Panacea 
Biotec Limited-5, Cipla Ltd.-3, Dabur Research 
Foundation-3, Nagarjuna Holdings Private Limited-3,  
2002 216 
CSIR-66, Carborundum Universal Limited-7, 
Biocon India Limited-6, Orchid Chemicals And 
Pharmaceuticals Limited-6, Dr. Reddy's Research 
Foundation-4, Aurobindo Pharma Limited-3, Blue 
Cross Laboratories Limited-3, Lupin Laboratories 
Limited-3, Neuland Laboratories Limited-3,  
 Source: Indian Patenting Activity in International and Domestic Patent 
 System: Contemporary Scenario (NISTADS, 2005)  
 
India’s international patenting activity is mainly in the US patent office. Earlier study 
has shown that there are 8 organisations that account f r almost 80% of the patenting 
in US. Organisations that had prolific patenting activity in US patent office are again 
the major players in using patent filing through PCT. However, there are also some 
new entrants such as Sahajanand Biotech Private Limited, Tejas Networks India Pvt. 
Ltd, Blue Cross Laboratories Limited, Neuland Laborat ies Limited. Aggregate 
activity in the overall period 1999-2002 is depicted in Table 6. 
 
Table 6 





CSIR-78, Dr. Reddy's Research Foundation-
12, Biocon India Limited-11, Carborundum 
Universal Limited-7, Orchid Chemicals And  
Pharmaceuticals Limited-6, Panacea Biotec Limited-
5, Dabur Research Foundation-5, Aurobindo Pharma 
Limited-3, Blue Cross Laboratories Limited-3, Lupin 
Laboratories Limited-3, Neuland Laboratories 
Limited-3, Cipla Ltd.-3, Nagarjuna Holdings Private 
Limited-3, Lakshmi Machine Works Limited-2,Nile 
Limited-1,Varma Trafag Limited –1 
Source: Indian Patenting Activity in International and Domestic Patent  System: 
Contemporary Scenario (NISTADS, 2005)  
 
The above Tables 5 and 6 underscore the importance of India joining PCT.  
Organisations are taking advantage of this new route to file patents in multiple 
countries. CSIR is among the top three organisations in the developing world in filing 
patents through the PCT route.  Foreign firms are also increasingly using this route for 
patent filing in India. Around 17833 applications have entered national phase from 
1998 onwards (i.e. in the Indian patent office) through this route in India and are 
being examined.  
 
Conclusions 
The study brings out the major changes in the Indian P tent Act that were required to 
meet India’s obligations to international agreements and treaties. The new patent act 
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(Patents Amendment Act 2005) has created a strong patent system in India. Overall 
the present act has increased the scope of patenting and provides stringent safeguards 
to the plaintiff i.e. patentee.  Defendant has to pr ve that he has not infringed upon a 
process patent and this would have far reaching consequence. The new act would play 
a major role in creating a technology driven market. Firms would increasingly try to 
create monopoly based on their patented technology. Indian firms primarily those that 
are in high technology areas would face increasing pressure, as patented products 
would enter the market.   
 
The pharmaceutical sector would face the maximum impact. On one hand newer 
drugs would enter the market, as earlier due to weak patent act foreign drug firms 
were reluctant to bring their high value drugs in India. On the other hand drug prices 
are expected to rise as generic drugs for drugs patented post 1995 would have to 
withdrawn. A patented drug provides the firm holding the said patent on it a 
monopoly and thus it can demand a very high price for the drug. It would be difficult 
for Indian firms to control the market.  Mailbox’ filing already shows the intention of 
foreign firms to bring in patented products in pharm ceuticals in the Indian market.  
 
One of the ways for Indian firms would be to increas  their own R&D and innovation 
activity to create patented products in pharmaceutials.  Patent trends show Indian 
firms are trying to become innovative firms. Product patents in pharmaceuticals were 
also obtained in the USPTO. However, it should be noted that through incremental 
modification of their products, changing dosage intensity and including minor 
features such as inert ingredients and the form, colour etc. it is possible to get product 
patents in pharmaceuticals in the USPTO. This may not be possible in the IPO, as 
patents would be granted only for any ‘new entity’ nvolving one or more inventive 
steps. 
 
Indian firms can also gain advantage through compulsory license. The amendment 
now gives the option of exporting drugs to a country, which makes a request for a 
generic drug. The only condition would be that the country where it can be exported 
should have no or insufficient manufacturing facility (this condition is imposed by 
TRIPS agreement). 
 
Broadly our examination shows that major changes made in the Indian Patent Act 
would have significant impact. The market would increasingly become technology 
driven. Indian firms would have to compete in the nw scenario.  The new act 
provides little scope for firms to infringe upon products that are protected by patents. 
This act may spur Indian firms to invest more in R&D and translate it to patented 
product. The significant impact of this act would be in pharmaceutical sector. Indian 
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